Showing 7671-7680 of 8681 results for "".
- Abbvie's Risankizumab Performs Well in Three Phase Three Psoriasis Studieshttps://practicaldermatology.com/news/abbvies-risankizumab-performs-well-in-three-phase-three-psoriasis-studies/2457991/Top-line results from three pivotal Phase 3 clinical trials show that risankizumab, an investigational interleukin-23 (IL-23) inhibitor,
- Long-Term Fat Reduction Seen Following Treatment with BTL Vanquish, Vanquish MEhttps://practicaldermatology.com/news/long-term-fat-reduction-seen-following-treatment-with-btl-vanquish-vanquish-me/2457992/Abdominal fat reduction achieved via BTL Vanquish and Vanquish ME lasts for at least four years, according to new long-term data released by the company. Both devices use radiofrequency (RF) energy to reduce fat. The study evaluated 13 in
- Dr. Daniel Siegel Joins DermTech's Advisory Boardhttps://practicaldermatology.com/news/dr-daniel-siegel-joins-dermtechs-advisory-board/2458000/DermTech, Inc., appointed Daniel M. Siegel, MD, to its Scientific Advisory Board. Dr. Siegel is a Clinical Professor of Dermatology and former Director of the Procedural Dermatology Fellowship at SUNY Downstate. He has served as a president of the American Academy of Dermatology (AAD) and is a pa
- Sun Dermatology Launches Absorica Tracker App to Help Patients Track Progresshttps://practicaldermatology.com/news/sun-dermatology-launches-absorica-tracker-app-to-help-patients-track-progress/2457999/Sun Pharma launched an Absorica Tracker App to help patients get the most out of their treatment. The easy-to-use interface is designed to help users to monitor their progress with Absorica (isotretinoin) treatment with features like medication and appointment reminders, monthly tips and checklis
- Exuviance Introduces New Detox Mud Treatmenthttps://practicaldermatology.com/news/exuviance-introduces-new-detox-mud-treatment/2458001/Exuviance is rolling out their new Detox Mud Treatment. The Exuviance Detox Mud Treatment is formulated with three key ingredients: 23 percent Active Charcoal, Clay, and NeoGlucosamine® for a refined, smoother complexion. The patented no
- Study: Risk of Indoor Tanning Dependency Highest in Women with Depressive Symptomshttps://practicaldermatology.com/news/study-risk-of-indoor-tanning-dependency-highest-in-women-with-depressive-symptoms/2458003/More than one in five young, white women who have used indoor tanning at least once in the past year show signs of being addicted to the high dose of ultraviolet (UV) radiation from tanning beds. In addition, women with symptoms of depression were three times more likely to meet the crite
- Menlo Therapeutics Expands Management Teamhttps://practicaldermatology.com/news/menlo-therapeutics-expands-management-team/2458006/Menlo Therapeutics Inc., a late stage biopharmaceutical company, is developing a neurokinin 1 (NK‐1) receptor antagonist (serlopitant) for the treatment of pruritus associated with various underlying conditions, and for the treatment of refractory chronic cough. The company, which continues to ad
- PruGen Pharmaceuticals Takes Action to Aid Hurricane Relief Effortshttps://practicaldermatology.com/news/prugen-pharmaceuticals-takes-action-to-aid-hurricane-relief-efforts/2458007/In the wake of several devastating and destructive hurricanes in the continental US and Puerto Rico, PruGen Pharmaceuticals is helping to those in need. The PruGen Foundation, a nonprofit organization founded by PruGen Pharmaceuticals and focused on philanthropic
- Ortho Dermatologics: Long-term Efficacy Data for Siliqhttps://practicaldermatology.com/news/ortho-dermatologics-long-term-efficacy-data-for-siliq/2458009/Siliq™ (brodalumab) injection provided sustained high levels of skin clearance (PASI 100) over more than two years in patients with moderate-to-severe psoriasis, according to data presented at the 2017 Fall Clinical Dermatology Conference in Las Vegas and reported by
- FDA Approves Stelara for Treatment of Adolescents with Moderate To Severe Plaque Psoriasishttps://practicaldermatology.com/news/fda-approves-stelara-for-treatment-of-adolescents-with-moderate-to-severe-plaque-psoriasis/2458010/The FDA approved an expanded indication for Janssen Biotech, Inc.'s Stelara (ustekinumab) for the treatment of adolescents (12 years of age or older) with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy. Today's approval marks a significant mile